Undisclosed CAB-HER2-CAR-T / BioAtla, Exuma Biotech - LARVOL DELTA

Clinical results of a phase 1 trial evaluating a HER2 directed CAR-T product selective for the tumor microenvironment (TME) in patients with GI and other solid tumor malignancies. (ASCO-GI 2025) - P1 | "The tumor metabolism regulated HER2 CAR-T product was generally well tolerated, with no DLTs, and evidence of radiologic objective response in patients with gastroesophageal cancer. Combined, the safety and activity observed in this study suggests that a previously challenging solid tumor antigen may be safely targeted by a CAR with affinity regulated by the metabolism of the TME. Enrollment for the study was complete as of 28-Feb-2024 (NCT04511871)."

Biomarker • Clinical • P1 data • Tumor microenvironment • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • HER-2

mRNA encoding a CAR specific stimulating protein (CSSP) mediates tumor metabolism regulated (TMR) CAR signaling for CAR-T expansion beyond the tumor microenvironment (AACR 2024) - "TMR-CAR-T cells can achieve proliferative capacity outside the tumor microenvironment using synthetic mRNA encoding CAR Specific Stimulatory Proteins. This novel mRNA approach may provide additional tools to promote the proliferation and/or persistence of solid tumor targeted CAR-T cells outside the tumor environment."

Biomarker • IO biomarker • Tumor microenvironment • Oncology • Solid Tumor • HER-2

Dr. Sid Kerkar Joins EXUMA Biotech as Vice President Oncology, R&D, Company Presents Data on HER2-Targeting CAR-T at AACR Tumor Immunology and Immunotherapy Conference (Canada Newswire) - "...EXUMA Biotech announced that an abstract titled 'Logic-gating HER2 CAR-T to the Tumor Microenvironment Mitigates On-Target, Off-Tumor Toxicity Without Compromising Cytotoxicity Against HER2-Over-Expressing Tumors' is being presented at the AACR Virtual Conference: Tumor Immunology and Immunotherapy, October 19-20, 2020. The 'logic-gated' HER2 CAR-T is designed to preferentially recognize HER2 in the tumor microenvironment (TME), thereby limiting on-target toxicity of low HER2 levels expressed in normal tissue."

Preclinical • Oncology